CSL: How a 1916 Government Laboratory Became a Global Plasma Giant

CSL is the most successful privatisation in Australian history and a useful corrective to the assumption that biotechnology value comes from discovering molecules. Its core business depends on collecting human plasma at scale, separating it into therapeutic proteins, and distributing them to patients with rare and serious conditions. The science is decades old; the moat is a global collection and manufacturing network that would take a competitor many years and billions of dollars to replicate.

How did a government department become a global biotech?

By being created for a purpose no private company would have served. The Commonwealth Serum Laboratories was established in 1916 because Australia’s geographic isolation made dependence on imported vaccines and antivenoms unacceptable during wartime. For decades it operated as a public health institution rather than a business.

Privatisation in 1994 was the pivot. CSL listed on the ASX at a valuation that now looks extraordinary in hindsight, and the newly independent company pursued a strategy of acquiring plasma fractionation capacity internationally — most consequentially through acquisitions in Switzerland and the United States that gave it global scale in a consolidating industry.

The strategic insight was that plasma therapeutics is a scale business rather than an innovation business. Whoever collects the most plasma, fractionates it most efficiently and extracts the most therapeutic value from each litre wins, because the raw material is the constraint. CSL built that network methodically over three decades while competitors consolidated around it.

Why is plasma collection the real business?

Because human plasma cannot be synthesised and its supply is limited by how many people donate. Collection occurs predominantly through paid donation centres, overwhelmingly in the United States where compensated donation is permitted, and building a centre network requires capital, regulatory approval, location selection and years of donor relationship building.

Each litre of plasma yields multiple products — immunoglobulin for immune deficiencies, albumin, clotting factors for haemophilia, and specialty proteins — and the economics depend on extracting maximum value from every litre. This is why yield improvement is a strategic priority rather than an operational one, and why CSL’s RIKA collection platform and iNomi manufacturing systems mattered enough to be reported as gross margin drivers.

The competitive structure follows from the capital intensity. A small number of large players — CSL, Grifols, Takeda and Octapharma among them — control most global capacity, because a new entrant would need collection centres, fractionation plants, regulatory approvals across dozens of countries and clinical evidence for each product. That is a decade-scale, multi-billion dollar barrier.

What went wrong recently?

Execution and communication rather than the underlying business. The FY2025 result was on target — revenue up 5%, net profit after tax up 17% with all business units contributing — but the healthcare sector had a difficult reporting season and CSL absorbed its biggest ever daily share price fall around the announcement.

The shareholder response was pointed. The annual general meeting delivered a second strike on remuneration, with shareholder concerns raised about performance, research and development returns, and communication. Analysts noted that while the fundamentals supported a longer-term view, management credibility needed to be rebuilt — an unusual assessment for a company with CSL’s record.

The demerger was subsequently deferred, which compounded the credibility issue. Announcing a major structural transaction and then delaying it invites questions about whether the original decision was properly considered, regardless of the merits of the delay itself.

Why demerge CSL Seqirus?

To remove seasonality and complexity from the group. CSL Seqirus is a global leader in seasonal influenza vaccines with a differentiated portfolio built on cell-based, adjuvant and self-amplifying mRNA technologies, and its earnings depend on annual flu seasons and immunisation rates in a way that plasma therapeutics does not.

The stated rationale is autonomy: an independent company can set its own strategic direction and pursue opportunities in a dynamic vaccines market, while the remaining group reduces complexity and becomes more agile. Gordon Naylor, a former President of CSL Seqirus, was named as chairman of the proposed entity.

The market context matters. Immunisation rates fell following the pandemic, particularly in the United States, while the European market has been stabilising, and vaccine technology is accelerating. A standalone vaccine company can raise capital, form partnerships and make acquisitions in that market on its own terms, which a division inside a plasma-focused group cannot do easily.

What does the transformation involve?

More than US$500 million in annual pre-tax cost savings targeted by FY2028 through operational efficiencies, alongside simplification of the operating model and reduction of organisational complexity. The company has also committed to disciplined reinvestment rather than growth for its own sake, and reintroduced a multi-year buyback with an initial A$750 million allocation from FY2026.

Product momentum supports the case. ANDEMBRY and HEMGENIX are newer products expected to contribute to growth, with HEMGENIX — a gene therapy for haemophilia B — approved across the European Union, United Kingdom, Canada, Switzerland and Australia and gaining approvals in Korea, Saudi Arabia, Hong Kong, Taiwan and Singapore during FY2025.

Guidance for FY2026 was group revenue growth of approximately 4% to 5% at constant currency, with CSL Behring expecting robust demand and improving gross margin following completion of the RIKA and iNomi platform rollouts. That is a solid, unspectacular outlook for a company the market had valued as a growth stock for two decades — and the repricing reflects that shift more than any operational failure.

What is CSL Vifor and why was it bought?

CSL Vifor is the iron deficiency and nephrology business acquired from Swiss group Vifor Pharma, giving CSL leading positions in intravenous iron therapy and in treatments for chronic kidney disease. It was the company’s largest acquisition and it diversified the group beyond plasma for the first time in decades.

The strategic logic was that CSL’s existing capability in specialty pharmaceuticals – clinical development, regulatory affairs, hospital sales channels and global distribution – transferred directly to a business selling to nephrologists and haematologists. The infrastructure was already built; the acquisition supplied additional products to run through it.

The execution has been more difficult than the logic implied. The business faces new competitive entrants, and the acquisition price was set in a period of higher valuations. CSL has stated that Vifor aims to maintain market-leading positions despite new entrants, which is a defensive rather than growth framing, and part of the credibility question the market has raised.

What does the privatisation record actually show?

That CSL is the outlier rather than the pattern. Australian privatisations have produced mixed results – Telstra delivered years of losses to retail investors who bought in the T2 and T3 offers, and several state asset sales have been contentious – while CSL delivered returns that made it one of the best-performing listed companies in Australian history.

The distinguishing feature was that CSL entered a globally consolidating industry with genuine technical capability and used its listing to acquire internationally. A privatised utility with a domestic monopoly has limited growth options; a privatised manufacturer with world-class capability in an expanding global market has many.

The lesson for privatisation policy is about what happens after the sale rather than the sale price. Assets sold into markets where the buyer can only extract value from existing customers produce different outcomes from assets sold into markets where the buyer can grow. That distinction is rarely the focus of privatisation debates, and it determines almost everything.

What should investors watch from here?

Gross margin recovery in CSL Behring, which management has said should continue improving following completion of the RIKA collection and iNomi manufacturing platform rollouts. That margin trajectory is the clearest available measure of whether the operational investment of recent years is converting into earnings.

Execution of the Seqirus demerger is the second, and the deferral raised the stakes. Delivering a substantial ASX-listed vaccine company on a credible timeline would restore some of the management credibility that analysts identified as needing rebuilding; a further delay or abandonment would compound the problem considerably.

The cost programme is the third. Targeting more than US$500 million in annual pre-tax savings by FY2028 is a specific, measurable commitment against which management can be assessed each reporting period, and it is the kind of promise that either builds or destroys credibility depending entirely on delivery.

One historical note that puts the privatisation in perspective. CSL listed in 1994 at a price that, adjusted for subsequent splits, represented a small fraction of what the shares later traded at, and the sale was criticised at the time for undervaluing a public asset. Whether the price was right depends entirely on whether one believes the government could have built the international plasma network that created the value – and the evidence from state-owned enterprises attempting global expansion elsewhere suggests it could not. Value was created after the sale by decisions the previous owner would not have made.

Frequently Asked Questions